CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor conferences. Details are as follows:
| BIO CEO & Investor Conference |
| Date: |
|
Monday, February 12, 2018 |
| Forum: |
|
Presentation |
| Time: |
|
1:30 p.m. ET |
| Location: |
|
New York |
| |
|
|
| SunTrust Robinson Humphrey 4th Annual Orphan Drug Day |
| Date: |
|
Tuesday, February 13, 2018 |
| Forum: |
|
1x1 Meetings |
| Location: |
|
New York |
A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investors:
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Source: Editas Medicine, Inc.
